Use of CFTR modulators in special populations, part 3: Solid organ transplant
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26396 ↗At a glance
Übersichtsarbeit in Pediatric Pulmonology, 2023. Written by Nour K Kadouh and 3 co-authors. Institution: Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA. Major MEDLINE topics: Organ Transplantation, Cystic Fibrosis. Cited 9 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: None.
Abstract (original language)
Background
Solid organ transplant (SOT) recipients with cystic fibrosis (CF) may benefit from the pulmonary and extrapulmonary benefits associated with CF transmembrane conductance regulator modulators. Nevertheless, evolution of modulator safety and efficacy data prompts consideration.
Methods
The search terms “transplant” AND “ivacaftor"(IVA) OR "lumacaftor"(LUM) OR "tezacaftor" (TEZ) OR "elexacaftor" (ELX) were utilized to conduct a scoping review of English articles from the period of January 1, 2012 to December 31, 2022. Search results from PubMed and Embase databases were reviewed by title and abstract for relevance. Included studies reported efficacy and safety outcomes of modulators in SOT recipients.
Results
One hundred thirty‐six patients from one cohort study (90 lung transplant recipients) and eight case reports and series (29 lung transplant recipients, 16 liver transplant recipients and one lung/liver transplant patient) were included. Post‐modulator initiation, 33 patients did not necessitate tacrolimus dose adjustments, 10 required dose uptitration, and 43 required dose reductions. Moreover, LUM/IVA use with azole antifungals may lead to subtherapeutic levels but opposing effects sustained tacrolimus levels. Liver transplant recipients were more likely to experience elevations in transaminases requiring pharmacologic or medical interventions. Majority of patients experienced improvements in pulmonary function, fasting blood glucose, hemoglobin, body mass index, and rhinosinusitis symptoms. However, intolerance or lack of benefit prompted discontinuation of ELX/TEZ/IVA in over 40% of lung‐transplant recipients in one study.
Conclusion
Modulator therapy has been reported to produce pulmonary and extra‐pulmonary benefits in the CF population with SOT. Considerations for modulator therapy initiation ought to include modulator pharmacokinetics, concomitant medications, and transplant type due to the complex nature of SOT recipients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
- Sanofi Medical Affairs, Bridgewater, New Jersey, USA.
- Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan, USA.
ORCID profiles: Nour K Kadouh, Joseph Elijah, Hanna Phan
Funding
- None
Cite
APA
Kadouh, N. K., Elijah, J., Fitzgerald, L. J., & Phan, H. (2023). Use of CFTR modulators in special populations, part 3: Solid organ transplant. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26396
Vancouver
Kadouh NK, Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 3: Solid organ transplant. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26396
BibTeX
@article{Kadouh2023,
author = {Kadouh, Nour K and Elijah, Joseph and Fitzgerald, Linda J and Phan, Hanna},
title = {Use of CFTR modulators in special populations, part 3: Solid organ transplant},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26396}
}
EUVIMED